Session: 702. CAR-T Cell Therapies: Basic and Translational: Poster III
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Translational Research
Methods: The Aib-CAR vector comprises a BCMA-CAR expression cassette and an inducible nuclear factor of activated T cells (NFAT)-driven CD24-CAR expression cassette integrated into a single lentiviral vector backbone. This design enables ubiquitous BCMA-CAR expression in all transduced T cells and inducible CD24-CAR expression via NFAT promoters activated by binding of the BCMA-CAR to its ligand on myeloma cells. To evaluate the performance of Aib-CAR-T cells, we established a panel of isogeneic myeloma cell lines derived from MM1.S (97% and 12% of these cells express BCMA and CD24, respectively). Derivative cell lines included a BCMA knockout (MM1.S-BCMAKO), a BCMA knockout with high CD24 expression (MM1.S-BCMAKO/CD24OE), and a BCMA / CD24 double knockout (MM1.S-BCMAKO/CD24KO). HEK293T kidney cells, genetically modified in the same way as the myeloma cells, were used as controls. CAR-T cells were co-cultured with myeloma cells at a 5:1 ratio for 24 hours. T-cell activation was assessed by measurements of both CD69 expression and release of cytokines IFN-γ, IL-2, and TNF-α into the cell co-culture supernatant.
Results: Co-culture of Aib-CAR-T effector cells with unmodified, parental MM1.S cells resulted in 89.5% target lysis after 24 hours. There was no difference in killing when Aib-CAR-T cells were compared to traditional dual BCMA-CD24 CAR-T cells. MM1.S-BCMAKO and MM1.S-BCMAKO/CD24OE cells resisted Aib-CAR-T cytotoxicity, which was in line with the finding that Aib-CAR-T cells were not activated (based on CD69 expression and production of IFN-γ, IL-2 and TNF-α) in the presence of these targets. In contrast, in the traditional dual BCMA-CD24 CAR-T cells efficiently lysed MM1.S-BCMAKO (62.3%) and MM1.S-BCMAKO/CD24OE (89.2%) cells, and increased both CD69 expression and cytokine production (IFN-γ, IL-2, and TNF-α) as one would have expected. In the case of MM1.S-BCMAKO/CD24KO target cells, neither Aib-CAR-T cells nor dual CAR-T cells exhibited significant cytotoxicity, thus demonstrating the specificity of the experimental model system employed. The same findings were obtained using gene-edited HEK293T cells, including the observation that Aib-CAR-T cells did not kill targets devoid of BCMA.
Conclusion: The results demonstrate that traditional dual-targeted BCMA-CD24 CAR-T cells can attack BCMA-CD24+ cells, potentially leading to on-target, off-tumor toxicity in vivo. In contrast, Aib-CAR-T cells must first be activated by binding to BCMA on the surface of myeloma cells before CD24+ targets, such as stem cell-like myeloma cells, can be recognized and killed. This design confines the activity of CD24-CAR to the myeloma microenvironment. Given that multiple myeloma cells grow in large clusters within the bone marrow, the design of Aib-CAR-T cells could significantly enhance safety by reducing on-target, off-tumor toxicity, thus suggesting their potential as a promising therapeutic approach for multiple myeloma. Importantly, inducible NFAT-driven CAR expression can be widely used for various target combinations in liquid and solid tumors, thus enhancing the safety and precision of dual-targeted CAR-T therapies.
Disclosures: Dhakal: Carsgen: Research Funding; Karyopharm: Honoraria, Speakers Bureau; C4 therapeutics: Research Funding; Pfizer: Consultancy, Honoraria, Speakers Bureau; Genentech: Consultancy, Honoraria; Sanofi: Research Funding; Acrellx: Research Funding; Medical College of Wisconsin: Current Employment; Bristol Myers Squibb: Honoraria, Research Funding; Janssen: Honoraria, Research Funding, Speakers Bureau.
See more of: Oral and Poster Abstracts